VXRT - Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2
- Vaxart ( NASDAQ: VXRT ) on Wednesday reported additional phase 1 data showing that its Spike/Nucleocapsid (S+N) oral tablet COVID-19 vaccine induced long-lasting mucosal IgA antibodies against COVID-19, and all tested coronaviruses.
- This additional data supports its potential to improve immune responses at mucosal surfaces and improve public health responses to the COVID-19 pandemic, the company said.
- it also said the vaccine had a higher neutralizing activity compared with convalescent samples.
- ( VXRT ) rose 2.3% before the bell.
For further details see:
Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2